TY - JOUR
T1 - Prevention of murine acute graft-versus-host disease by recipient-derived TGFβ1-treated dendritic cells
AU - Mou, H. B.
AU - Lin, M. F.
AU - Cen, H.
AU - Huang, H.
AU - Cai, Z.
N1 - Funding Information:
This work was supported by China's National Natural Science Foundation Grant 30270571 and China's Ministry of Education Grant 20020335080.
PY - 2004/6
Y1 - 2004/6
N2 - Acute graft-versus-host disease (GVHD) remains the major barrier to allogeneic bone marrow transplantation (allo-BMT). Evidence has accumulated that transforming growth factor β1-treated dendritic cells (TGFβ-DC), deficient in surface costimulatory molecules, inhibit alloantigen-specific T-cell responses and induce graft hyporeactivity. To analyze the effect of TGFβ-DC on GVHD after allo-BMT, 5.0 × 106 recipient-derived TGFβ-DC were injected into C57BL/6 (H-2b) with bone marrow-splenocyte grafts from major histocompatibility complex (MHC) disparate BALB/c mice (H-2d). Survival analysis showed TGFβ-DC cotransplantation resulted in significant prolongation of allograft survival, namely a mean survival time (MST) of 44.3 ± 4.5 days, versus the untreated MST of 9.5 ± 0.6 days (P < .01). However, mature DC aggravated the GVHD with an MST of 6.6 ± 0.6 days (P < .01). In addition, the third-party C3H-derived TGFβ-DC did not enhance the survival rate (MST = 9.7 ± 0.5 days). Furthermore, serum IFN-γ, IL-12, and IL-18 levels in TGFβ-DC cotransplanted mice were reduced compared with untreated BMT hosts, while serum IL-10 levels were not changed. These results suggest that TGFβ-DC cotransplantation may attenuate the severity of GVHD after BMT.
AB - Acute graft-versus-host disease (GVHD) remains the major barrier to allogeneic bone marrow transplantation (allo-BMT). Evidence has accumulated that transforming growth factor β1-treated dendritic cells (TGFβ-DC), deficient in surface costimulatory molecules, inhibit alloantigen-specific T-cell responses and induce graft hyporeactivity. To analyze the effect of TGFβ-DC on GVHD after allo-BMT, 5.0 × 106 recipient-derived TGFβ-DC were injected into C57BL/6 (H-2b) with bone marrow-splenocyte grafts from major histocompatibility complex (MHC) disparate BALB/c mice (H-2d). Survival analysis showed TGFβ-DC cotransplantation resulted in significant prolongation of allograft survival, namely a mean survival time (MST) of 44.3 ± 4.5 days, versus the untreated MST of 9.5 ± 0.6 days (P < .01). However, mature DC aggravated the GVHD with an MST of 6.6 ± 0.6 days (P < .01). In addition, the third-party C3H-derived TGFβ-DC did not enhance the survival rate (MST = 9.7 ± 0.5 days). Furthermore, serum IFN-γ, IL-12, and IL-18 levels in TGFβ-DC cotransplanted mice were reduced compared with untreated BMT hosts, while serum IL-10 levels were not changed. These results suggest that TGFβ-DC cotransplantation may attenuate the severity of GVHD after BMT.
UR - http://www.scopus.com/inward/record.url?scp=3142642644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3142642644&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2004.05.046
DO - 10.1016/j.transproceed.2004.05.046
M3 - Article
C2 - 15251394
AN - SCOPUS:3142642644
SN - 0041-1345
VL - 36
SP - 1604
EP - 1606
JO - Transplantation proceedings
JF - Transplantation proceedings
IS - 5
ER -